GLP-1 Medications for Weight Loss vs Type 2 Diabetes: What's the Difference?

One of the most common points of confusion in the GLP-1 conversation is this: patients see that Ozempic and Wegovy contain the same active ingredient, semaglutide. They hear that people use them for both type 2 diabetes and weight loss. They wonder whether the medication prescribed for diabetes is the same thing they're reading about for obesity.

The short answer is: the drug is identical. The dose and the paperwork are different.

This article explains what those differences mean in practice, how NHS access varies depending on indication, and how Mounjaro fits into the picture.

The Core Explanation: Same Molecule, Different Doses

Semaglutide is a GLP-1 receptor agonist. It was developed by Novo Nordisk and first licensed for type 2 diabetes management at doses of 0.5 mg and 1 mg weekly (as Ozempic) and later 2 mg weekly. The observation during diabetes trials that semaglutide produced significant weight loss led to a separate development programme for obesity, resulting in Wegovy, which is semaglutide at a higher dose (2.4 mg weekly at therapeutic dose) licensed specifically for chronic weight management.

The molecule that binds to the GLP-1 receptor is chemically identical in both products. The difference is the dose, the licensed indication, and consequently the regulatory pathway.

Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg): Licensed for type 2 diabetes management. Available on NHS prescription for people with type 2 diabetes.

Wegovy (semaglutide 2.4 mg): Licensed for chronic weight management in adults with BMI 30+, or BMI 27+ with a weight-related health condition. Available privately and via NHS specialist weight management services.

How Each Drug Works

Understanding the mechanism helps clarify why these medications work for both conditions.

GLP-1 (glucagon-like peptide-1) is a hormone naturally released by the intestine in response to food. It has several effects:

• Stimulates the pancreas to release insulin in response to glucose (glucose-dependent, meaning it does not cause hypoglycaemia on its own)
• Suppresses glucagon secretion, reducing glucose output from the liver
• Slows gastric emptying, which flattens post-meal glucose spikes
• Acts on the hypothalamus to reduce appetite and food noise
• Promotes satiety signals to the brain

In type 2 diabetes, the primary target is blood glucose control. The insulin-stimulating, glucagon-suppressing, and gastric-slowing effects are all beneficial for glycaemic management. Weight loss is a significant secondary benefit.

In obesity treatment without diabetes, the primary target is weight. The appetite-suppressing and satiety-enhancing effects are the main mechanism. Blood glucose improvement is a significant secondary benefit.

The higher dose used in Wegovy (2.4 mg versus 1-2 mg for Ozempic) produces proportionally greater appetite suppression. This is why the average weight loss in the STEP 1 obesity trial (14.9%) is greater than the typical weight reduction seen in diabetes trials at lower doses.

Ozempic, Wegovy, and Mounjaro: The Comparison

Mounjaro is a different active ingredient: tirzepatide acts on both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual agonism appears to produce greater weight loss than GLP-1 agonism alone, which is why the SURMOUNT-1 trial data are more dramatic than STEP 1. However, the underlying mechanism and the eligibility criteria are analogous.

NHS Access: How It Differs

This is where the distinction between indications has the most practical impact.

Type 2 Diabetes: The Simpler Route

If you have type 2 diabetes, your GP can prescribe Ozempic on the NHS today. No referral to a specialist is needed. The prescribing decision follows NICE guidelines for glucose-lowering medication in type 2 diabetes. Ozempic is on the national formulary and cost-effective at the diabetes doses.

The NHS also covers Mounjaro (tirzepatide) for type 2 diabetes following its NICE technology appraisal. Your GP or diabetes care team can prescribe it.

Obesity Without Diabetes: The Restricted Route

For people seeking GLP-1 treatment for obesity without type 2 diabetes, the NHS pathway is more complex. Wegovy at obesity doses is not routinely prescribable by a GP. Access is currently via:

1. Specialist NHS weight management services, which require referral and have waiting lists
2. NHS pilot programmes in specific integrated care systems
3. The NHS England national rollout of Wegovy, which is being phased in through weight management services

The NHS rollout is expanding, but as of 2026, many women are not able to access NHS Wegovy promptly. Private clinics such as Voy and Lola Health exist specifically to serve this gap.

Off-Label Prescribing: The Risks

You may encounter online discussions about using Ozempic (at diabetes doses) for weight loss, or prescribers offering Ozempic off-label for obesity. This deserves clarity.

Off-label prescribing is legal in the UK when a clinician judges it to be in the patient's best interest. However:

• Ozempic at 1-2 mg doses produces less weight loss than Wegovy at 2.4 mg. If the goal is obesity treatment, the licensed dose is more effective.
• Supply issues with Ozempic have been severe in recent years because of demand from non-diabetic users. Prescribing Ozempic off-label for weight loss contributes to reduced availability for diabetic patients who depend on it for glucose control. This is an ethical consideration worth taking seriously.
• Insurance and clinical governance implications may differ for off-label prescribing. If you are using Ozempic off-label, ensure your prescriber has explicitly documented the indication.

Wegovy, licensed for obesity, is the appropriate choice for women seeking GLP-1 treatment for weight management without type 2 diabetes. Mounjaro similarly has its own obesity licence.

What This Means for Your Treatment Decision

If you have type 2 diabetes and your GP is not already discussing GLP-1 treatment, ask. The NICE guidance recommends considering semaglutide or tirzepatide for many patients with T2D, and the NHS pathway is available.

If you have obesity without diabetes and want GLP-1 treatment, the private clinic route is the most direct current option. For a comparison of the main UK private clinics, see best GLP-1 clinics in the UK 2026.

If you have both obesity and related conditions such as PCOS, the overlap between the diabetes and obesity indications is clinically relevant. GLP-1 treatment improves insulin sensitivity and hormonal markers in PCOS independently of whether a formal T2D diagnosis exists. See GLP-1 for PCOS UK for the condition-specific evidence.

Primary Endpoints: What the Trials Measure Differently

The difference in licensed indications also reflects a difference in what the clinical trials were designed to measure:

Diabetes trials (SUSTAIN series for semaglutide, SURPASS series for tirzepatide): The primary endpoint is HbA1c reduction. Weight loss is a secondary endpoint. The primary goal is glucose control.

Obesity trials (STEP series for semaglutide, SURMOUNT series for tirzepatide): The primary endpoint is percentage weight loss from baseline. Metabolic improvements (blood glucose, blood pressure, lipids) are secondary endpoints. The primary goal is weight reduction.

This matters because a medication that is licensed for diabetes has been proven to control glucose. A medication licensed for obesity has been proven to produce meaningful weight loss. The evidence base is different, even if the molecule is the same.

Blood Tests: What to Monitor

Whether you are taking GLP-1 medication for diabetes or weight loss, certain blood tests should be monitored. These are covered in detail at GLP-1 blood tests before starting UK.

For private testing outside of NHS monitoring:

Starting Treatment: What to Read First

If you are starting GLP-1 treatment, whether for diabetes or obesity, the following guides are the most practically useful:

• Your first month on GLP-1: Week-by-week guide to what to expect
• GLP-1 side effects guide: The full side effect profile and management
• Wegovy side effects in women: Women-specific effects including menstrual changes
• Protein on GLP-1: complete guide: Why protein matters and how to hit targets on suppressed appetite